Theme Leader, New Marketplace
Member of the NEJM Catalyst Leadership Board

Leemore Dafny, PhD

Bruce V. Rauner Professor of Business Administration
Harvard Business School


Leemore Dafny is the Bruce V. Rauner Professor of Business Administration at the Harvard Business School, and a member of the faculty of the Kennedy School of Government. Prior to joining Harvard in 2016, she served as Director of Health Enterprise Management, Herman Smith Professor of Hospital and Health Services Management, and a professor of strategy at the Kellogg School of Management at Northwestern University.

Professor Dafny’s research examines competitive interactions among payers and providers of health care services, and the intersection of industry and public policy. Her work has been published in academic journals such as The American Economic Review and The New England Journal of Medicine, and featured in popular media such as The New York Times and The Wall Street Journal. Current projects include studies of consolidation in the U.S. hospital industry and the kidney dialysis industry, products and pricing on the public health insurance exchanges, co-payment coupons for prescription drugs, and the implications of for-profit ownership of insurance companies.

Professor Dafny graduated summa cum laude from Harvard College and worked as a consultant with McKinsey & Company prior to earning her PhD in economics from the Massachusetts Institute of Technology. She has won several teaching awards as well as Kellogg’s leading research prize, the Stanley Reiter Best Paper Award. Professor Dafny is a research associate of the National Bureau of Economic Research, an Associate Editor of Management Science, and a board member of the American Society of Health Economists and the Health Care Cost Institute.

Professor Dafny’s expertise spans both the public and private sectors. She serves on the Panel of Health Advisers for the Congressional Budget Office. In 2012–2013, she was Deputy Director for Health Care and Antitrust in the Bureau of Economics at the Federal Trade Commission. She also advises companies, government agencies, and nonprofits on a variety of issues including antitrust matters, strategic decisions, and public policy.

A Prescription for the Ailing U.S. Health Care Market - Leemore Dafny talk still

New Marketplace

Prescription for an Ailing U.S. Health Care Market

Three components for treating the unhealthy, uncompetitive U.S. health care market — beginning with a buyer’s revolt.

Why Employers Drag Feet on Value-Based Insurance and Reshaping Health Care Coverage: A Classic Public Good Problem Panel Clip Still

New Marketplace

Reshaping Care Coverage: A Public Good Problem

The companies most capable of leading transformation in health care coverage are the ones that least need to.

Why Employers Drag Feet on Value-Based Insurance and Reshaping Health Care Coverage: A Classic Public Good Problem Panel Clip Still

New Marketplace

Why Employers Drag Feet on Value-Based Insurance

Why are employers hesitating? What do they value and want to invest in when it comes to health care payment plans?

Robert Gavin head shot

New Marketplace

Amazon and CVS: Short-Lived Unicorns in Health Care, or Healers of the “Tapeworm”?

Will Amazon–Berkshire Hathaway–JP Morgan and CVS-Aetna change the health care game? To one health care employer purchaser, these announcements feel a lot like Groundhog Day.

Simplified Chain of Production for Primary Care Services Generating Retail Prescriptions. Solid arrows indicate contractual relationships or ownership, and the dashed arrow indicates referral for prescription.

New Marketplace

Does CVS–Aetna Spell the End of Business as Usual?

What might one of the largest mergers in history mean for the health care delivery system?

How Aligned Are Payers and Providers in Working Together to Achieve Value-Based Care

New Marketplace

New Marketplace Survey: Payers and Providers Remain Far Apart

Health care stakeholders are not aligned in important goals and in large part are not working together to achieve value-based care, according to the NEJM Catalyst Insights Council. They are waiting on government regulators to change the payment model — including, possibly, single-payer health care.

Marc Harrison and Leemore Dafny head shots

New Marketplace

Fair Pharma? Intermountain’s New Generic Drug Company

“What we aim to do is to create something akin to a public utility that is going to put public good first.”

Resolving the Payer-Employer Disconnect with Health Plans Panel Clip Still

New Marketplace

Resolving the Payer-Employer Disconnect

Payers need to break out of their insular way of thinking.

Payment Reform Is a Play We Are All Watching: Leemore Dafny Talk Still

New Marketplace

Payment Reform Is a Play We’re All Watching

We can’t get what we want in payment reform if we’re not clear about what that is.

Jumping into Value-Based Reimbursement with Two Feet Panel Clip Still

New Marketplace

Jumping into Value-Based Reimbursement with Two Feet

What payers would like to see when it comes to engagement in value-based reimbursement and building healthier outcomes.

Load More
Insights Council

Have a voice. Join other health care leaders effecting change, shaping tomorrow.

Apply Now